Chatziantoniou C, Dussaule J C
INSERM U.489, Hòpital Tenon, and AP-HP, Laboratoire de Physiologie, Facultè de Mèdecine St Antoine, Paris, France.
Curr Opin Nephrol Hypertens. 2000 Jan;9(1):31-6. doi: 10.1097/00041552-200001000-00006.
The present review focuses on recent data regarding the role of endothelin as a mediator of renal vascular fibrosis. Following a brief description of the endothelin system, the question of whether endothelin is involved in hypertensive mechanisms is examined in experimental, genetic and transgenic animal models. Evidence is provided that implicates endothelin as an important factor of the development of tissue fibrosis and end-organ damage associated with hypertension, with particular emphasis on renal vascular fibrosis. Data indicating that endothelin interacts with other vasoconstrictor systems, such as angiotensin II, are also considered. Finally, results from preliminary clinical studies using endothelin receptor antagonists to treat cardiac and renal pathologies are briefly discussed.
本综述聚焦于内皮素作为肾血管纤维化介质的最新数据。在对内皮素系统进行简要描述后,通过实验、基因和转基因动物模型研究了内皮素是否参与高血压机制的问题。有证据表明内皮素是与高血压相关的组织纤维化和终末器官损伤发展的重要因素,尤其强调肾血管纤维化。还考虑了表明内皮素与其他血管收缩系统(如血管紧张素II)相互作用的数据。最后,简要讨论了使用内皮素受体拮抗剂治疗心脏和肾脏疾病的初步临床研究结果。